Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
Managing the Growing Expansion of Copay Accumulators
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.
What Do Payers Think About Digital Health Technologies
How are payers thinking about apps, wearables and other digital health technologies?